|
|
 |
|
|
| Marketing |
|
Eisai has established regional headquarters in each of the following regions: Japan; the Americas; Europe; China and Asia/Oceania & the Middle East. These regional headquarters formulate strategies for each region.
|
|
| Business in Japan |
|
[Japan Business Headquarters (JBHQ)]
In light of the recent medical trends in Japan focused on prevention, disease management, and the latest treatments, the Company established a Japan Business Headquarters (JBHQ) and has been implementing an integrated business strategy for the four business operations of Eisai in Japan consisting of diagnostics, ethical drugs, consumer health care products, and generics. Based on this unique and integrated system, the Company aims to achieve a close collaboration of these four business operations in supplying quality product in sufficient quantities; generating services; raising disease awareness, taking into account consultation, diagnosis, and treatment; facilitating the concurrent use of diagnostic agents and pharmaceutical products in the same therapeutic area; and supplying high-quality products and information on generic drugs through cooperation between the Company and its subsidiaries. By doing so, the Company is committed to generating Customer Joy among our stakeholders, including patients and health care professionals, and thereby achieve continuous growth |
|
[Prescription Pharmaceuticals Business in Japan]
(Aricept®)
(Pariet®) |
|
In Japan, Eisai's prescription pharmaceutical business is centered on drugs prescribed by medical professionals in hospitals and clinics. With special emphasis on, Aricept®, a drug for treating mild-to-moderate Alzheimer's disease, and Pariet®, a proton pump inhibitor for treating ulcers and gastroesophageal reflux disease, Eisai focuses on its sales efforts in same areas such as neurology, the digestive system, locomotory system and immunology & inflammation. Sales activities are aimed at developing efficient and effective promotional activities for the company's products in those areas.
We particularly consider the prescription pharmaceutical business to play an important role in contributing to medicine by providing professionals in this field with highly reliable product information based on evidence from the most recent medical breakthroughs, as well as ensure a stable supply of high-quality products to medical institutions. To achieve this, we provide the most recent and appropriate usage information for our products, collect constantly expanding and evolving information on diagnostics and treatment trends in the medical field, and validate our overall activities. |
In recent years, as part of the reforms in the medical service in Japan, there has been an accelerated movement among medical institutions to separate their functions and to promote coalition. Therefore, today's health care environment demands action on providing more detailed, high quality medical-related information. In this regard, we implemented reforms in management structure and developed training and education modules to enhance our MRs' knowledge and skills so that we can respond quickly and flexibly to these types of market changes in the future.
Through the conduct of various educational activities, Eisai contributes to the dissemination of information related to drugs, as well as information on various disease conditions to patients, their families and caregivers. |
|
[Consumer Healthcare Products in Japan (OTC Drugs)]
The consumer health care products business is centered on over-the-counter products sold at drugstores and pharmacies. It also handles products that support healthcare such as quasi-drugs. Eisai refers to all of these products collectively as consumer health products.
Some products that consumers have become familiar with through television commercials and other forms of advertising include Chocola BB Plus®, a remedy for canker sores that also helps to relieve dry skin, Selbell®, a remedy that adjusts the protection of mucous in weakened stomachs, and Nabolin® EB tablets for treating persistently stiff shoulders and numbness in hands and feet. Other Eisai products include Saclon®, a fast and effective green-colored medicine for the relief and protection of the stomach due to alcohol consumption or excessive acid secretion, and Travelmin®, an effective remedy for motion sickness that can be taken even after experiencing symptoms. These Eisai products are used and relied on by many customers.
Eisai launched “Crystal Veil”, an allergen screen topical gel, in October 2009, and “Chocola BB® Royal T”, new pharmaceutical tablets of the Chocola BB series, in February 2010. Eisai intends to bolster these useful new products for consumer health.
The consumer health care products business is the most visibly active of all Eisai's businesses from the perspective of patients and consumers. Ideas based on comments received directly from customers as well as from pharmacies and drugstore pharmacists are used in developing and improving high-quality products that provide benefits to customers. One example is the shrink-wrap packaging to prevent product tampering.
Eisai is undertaking product development and marketing in the consumer health care products business with the aim of meeting the self-medication needs of customers and contributing to further improving quality of life (QOL). |
|
 |
|
Page Top  |
| Business in the U.S. (Sales) |
The Company's U.S. business had been centered on its major products, namely Aricept®, an Alzheimer's disease treatment, and AcipHex® (brand name in Japan: Pariet®), a proton pump inhibitor. More recently, the Company has enhanced its business platform in the United States as well as successfully made a full-scale entry into the field of oncology through the acquisition of oncology-related products from Ligand Pharmaceuticals and also the acquisitions of Morphotek, Inc., and MGI PHARMA, INC., thus transforming its business focus into the growing segment.
At the same time, the Company will continue its development efforts with regard to Aricept® and AcipHex®, both treatments in high demand, seeking to increase their usefulness by adding new formulations including a transdermal patch formulation, extended release formulation, or long-acting formulation, as well as new indications to increase patient value. In addition, the Company will develop and make available on the market its portfolio of oncology products and critical care products, such as its sepsis treatment.
The sales force in the U.S. comprises approximately 920 MRs (as of September 2009). Divided into several specialty groups, the MRs are expediting marketing activities for the extensive line of products in the U.S.
Under the new administration, the U.S. pharmaceutical market is expected to undergo significant change. The emphasis and value placed on innovation, however, will likely remain unchanged. Accordingly, the Company believes that it will be able to respond appropriately to the expected changes in the U.S. pharmaceutical market by further promoting its ongoing efforts in the early development of innovative drugs and stable supply of high quality products.
|
| Page Top |
| Business in Europe (Sales) |
With sales subsidiaries located in Germany, France, Italy, Spain, Switzerland, Sweden, Portugal, Belgium, Austria and the U.K., where Eisai's European holding and regional headquarters are located, Eisai's products are available in 20 European countries (as of September 2009).
The Company's European business is moving towards a High-Efficiency Business Model, a unique and new business model that seeks to generate higher efficiency and productivity through the integration of its operational functions, including marketing, medical, finance, and IT, and where the Company's subsidiaries in Europe specialize in the marketing of its products. The cornerstone of this model is the European Knowledge Centre (EKC) in Hatfield in the United Kingdom, a new facility opened in June 2009. The EKC houses the production, drug discovery research, clinical research, marketing, and headquarters functions for the European region, as well as features to support smooth cross-functional communication so as to facilitate knowledge creation in pursuit of Eisai's commitment to achieving Customer Joy in Europe.
Eisai's business in Europe has been driven by its core products Aricept® and Pariet®. In addition, Eisai is actively expanding its product portfolio with in licensing products such as anti-epileptic agents Zonegran®, Inovelon®, and Zebinex®, as well as Prialt®, a therapy used to treat severe chronic pain, and NeuroBloc®, a treatment for cervical dystonia, while placing a focus on epilepsy as the area with high unmet medical needs seeking to make contributions to increasing the benefits to patients and their families. |
| Page Top |
| Business in China and Asia/Oceania & the Middle East (Sales) |
Eisai has been actively conducting business in Asia since the 1960s. The Company is strengthening its strategic product portfolio to meet the various characteristics and medical needs of each market.
[China]
In China, the Company seeks to contribute to the disease management of patients and enhancement of their quality of life by proactively introducing products tailored to the distinctive disease characteristics seen in China, while at the same time strengthening its presence with Aricept® and Pariet®, the Company's major global products. Furthermore, the Company is aiming to achieve continuous growth by expanding its sales network in the Chinese market.
[Asia/Oceania & the Middle East (AOME)]
In its Asia/Oceania & the Middle East (AOME) business, the Company is promoting business activities that enable it to increase the quality of a range of products, information, and services that have been strategically tailored to the medical needs of each market. In December 2009, the Company established the Eisai Knowledge Centre, India as its fourth knowledge creation base. With Active Pharmaceutical Ingredients (APIs) and formulation manufacturing and API process research functions integrated on one site, the new facility serves to strengthen the Company's capabilities as it looks to become a global hub capable of ensuring a stable supply of high quality pharmaceutical products. |
|
|
